By Fineline Cube 
Jiangxi Institute of Biological Products Inc., China’s largest provider and exporter of human tetanus antitoxin (human TAT), has submitted an initial public offering (IPO) filing to the Hong Kong Stock Exchange. The move follows the company’s strong market performance and strategic growth, positioning it for further expansion in global markets.
Market Leadership and Financial Performance
A former branch of the Shanghai Institute of Biological Products, Jiangxi Institute of Biological Products holds a dominant market share of 65.8% in China and 36.6% globally, based on 2024 sales volume. The company’s human TAT products are included in key national lists, including the National Drug Reimbursement Drug List, National Essential Drug List, and National Emergency (Rescue) Drug List in China. In 2024, the company reported revenues of RMB 220.8 million (USD 30.2 million) and profits of RMB 75.1 million (USD 10.3 million), reflecting a compound annual growth rate (CAGR) of 24.7% and 68.5% for revenue and profit, respectively.
Growth Strategy and Future Outlook
The IPO filing underscores Jiangxi Institute of Biological Products’ commitment to leveraging its market leadership to expand its global footprint. With robust financial performance and a strategic focus on innovation and market expansion, the company is well-positioned to capitalize on growing demand for human TAT products both domestically and internationally.-Fineline Info & Tech